Review of pharmacokinetics and pharmacodynamics of antimicrobial agents

被引:30
作者
Estes, L [1 ]
机构
[1] Mayo Clin, Hosp Pharm Serv, Rochester, MN 55905 USA
关键词
D O I
10.4065/73.11.1114
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pharmacokinetics is a science that has long been used in ascertaining the appropriate antimicrobial dose. It refers to the disposition of drugs in the body and includes absorption, bioavailability, distribution, protein binding, metabolism, and elimination. Pharmacodynamics is a newer science that relates to the interaction between the drug concentration at the site of action over time and the desired antimicrobial effect. This article reviews the principles of pharmacokinetics and pharmacodynamics as well as the clinical application of these two sciences to design antimicrobial dosing regimens for optimal results in individual patients.
引用
收藏
页码:1114 / 1122
页数:9
相关论文
共 75 条
[31]   Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans [J].
Klepser, ME ;
Wolfe, EJ ;
Pfaller, MA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (03) :397-401
[32]   Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans [J].
Klepser, ME ;
Wolfe, EJ ;
Jones, RN ;
Nightingale, CH ;
Pfaller, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) :1392-1395
[33]   COMPARATIVE ANTIBIOTIC DOSE-EFFECT RELATIONS AT SEVERAL DOSING INTERVALS IN MURINE PNEUMONITIS AND THIGH-INFECTION MODELS [J].
LEGGETT, JE ;
FANTIN, B ;
EBERT, S ;
TOTSUKA, K ;
VOGELMAN, B ;
CALAME, W ;
MATTIE, H ;
CRAIG, WA .
JOURNAL OF INFECTIOUS DISEASES, 1989, 159 (02) :281-292
[34]  
LEVISON ME, 1995, INFECT DIS CLIN N AM, V9, P483
[35]   THE POSTANTIBIOTIC EFFECT [J].
MACKENZIE, FM ;
GOULD, IM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 32 (04) :519-537
[36]   Twenty-four-hour area under the concentration-time curve MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model [J].
MadarasKelly, KJ ;
Ostergaard, BE ;
Hovde, LB ;
Rotschafer, JC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (03) :627-632
[37]  
MANN HJ, 1987, CLIN PHARMACY, V6, P148
[38]   CLINICAL-RESPONSE TO AMINOGLYCOSIDE THERAPY - IMPORTANCE OF THE RATIO OF PEAK CONCENTRATION TO MINIMAL INHIBITORY CONCENTRATION [J].
MOORE, RD ;
LIETMAN, PS ;
SMITH, CR .
JOURNAL OF INFECTIOUS DISEASES, 1987, 155 (01) :93-99
[39]   ASSOCIATION OF AMINOGLYCOSIDE PLASMA-LEVELS WITH THERAPEUTIC OUTCOME IN GRAM-NEGATIVE PNEUMONIA [J].
MOORE, RD ;
SMITH, CR ;
LIETMAN, PS .
AMERICAN JOURNAL OF MEDICINE, 1984, 77 (04) :657-662
[40]   CLINICAL PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS IN PATIENTS WITH LIVER-DISEASE - AN UPDATE [J].
MORGAN, DJ ;
MCLEAN, AJ .
CLINICAL PHARMACOKINETICS, 1995, 29 (05) :370-391